伊沙妥昔单抗联合西米普利单抗双靶向CD38与PD-1治疗复发/难治性NK/T细胞淋巴瘤的疗效
这项2期试验评估西米普利单抗联合伊沙妥昔单抗治疗复发/难治性结外NK/T细胞淋巴瘤的疗效与安全性。37例入组患者完全缓解率为51%(19/37),超过40%的主要终点,客观缓解率65%(24/37)。中位随访30.2个月,中位无进展生存期9.5个月,中位总生存期未达到,3级及以上不良事件发生率32%,无治疗相关死亡。
要点
- 37例复发/难治性结外NK/T细胞淋巴瘤患者中完全缓解率为51%(19/37),超过预设40%的主要终点。
- 客观缓解率65%(24/37),中位无进展生存期9.5个月,中位总生存期未达到。
- 3级及以上不良事件发生率32%,无治疗相关死亡。
核心结论
- 伊沙妥昔单抗联合西米普利单抗在复发/难治性结外NK/T细胞淋巴瘤中显示出持续的抗肿瘤活性和可控的安全性。
研究设计与样本
- 这项2期试验共入组37例复发/难治性结外NK/T细胞淋巴瘤患者,旨在评估西米普利单抗联合伊沙妥昔单抗的疗效与安全性。
主要发现
- 完全缓解率为51%(19/37),超过主要终点40%,客观缓解率为65%(24/37)。
- 中位随访30.2个月(95%CI 25.6-34.8个月)时,中位无进展生存期为9.5个月(95%CI 1.4-17.6个月),中位总生存期未达到。
- 达到完全缓解的患者接受的中位周期数为28个(范围4-33个周期),缓解者(n=24)的中位缓解持续时间为29.4个月(95%CI 15.4-43.4个月)。
- 缓解者中观察到破坏PD-L1 3'非翻译区的结构变异和高程序性死亡配体1(PD-L1)表达。
- 大多数不良事件为轻度(1-2级),3级及以上事件发生率为32%,无治疗相关死亡。
关键数值与推荐
- 符合条件的患者接受西米普利单抗(第1天和第15天250 mg)和伊沙妥昔单抗(第2天和第16天10 mg/kg)静脉给药,每4周一次,共6个周期。
- 缓解者随后接受西米普利单抗(350 mg)和伊沙妥昔单抗(10 mg/kg)每3周一次,最长24个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to assess the efficacy and safety of combining cemiplimab, an anti-programmed cell death protein 1 (PD-1) antibody, with isatuximab, an anti-CD38 antibody, in relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). The hypothesis was that CD38 blockade could enhance the antitumor activity of PD-1 inhibitors. Eligible patients received cemiplimab (250 mg on days 1 and 15) and isatuximab (10 mg/kg on days 2 and 16) IV every 4 weeks for 6 cycles. Responders then received cemiplimab (350 mg) and isatuximab (10 mg/kg) every 3 weeks for up to 24 months. The primary end point was the complete response (CR) rate based on the best response. Of 37 patients enrolled, the CR rate was 51% (19/37), exceeding the primary end point of 40%, and the objective response rate was 65% (24/37). After a median follow-up of 30.2 months (95% confidence interval [CI], 25.6-34.8 months), the median progression-free survival was 9.5 months (95% CI, 1.4-17.6 months), whereas the median overall survival had not yet been reached. Patients achieving CR received a median of 28 cycles (range, 4-33 cycles), and the median duration of response for responders (n = 24) was 29.4 months (95% CI, 15.4-43.4 months). Structural variations disrupting the 3'-untranslated region of PD-L1 and high programmed death ligand 1 (PD-L1) expression were observed in responders. Most adverse events were mild (grade 1-2), with grade ≥3 events (32%) and no treatment-related deaths. The combination of isatuximab and cemiplimab demonstrated sustained antitumor activity and a manageable safety profile in R/R ENKTL. This phase 2 trial is registered at www.clinicaltrials.gov as number NCT04763616.
引用
- Kim SJ, Lim JQ, Yoon SE, et al. Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma. Blood. 2025. PMID: 40073374. doi:10.1182/blood.2024027109
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。